Seaport Therapeutics, Inc.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines. The company leverages its proprietary Glyph technology platform to create therapeutic candidates for conditions such as depression and anxiety disorders. The Glyph platform is designed to enable oral bioavailability, bypass first-pass metabolism, and reduce liver enzyme elevations or hepatotoxicity and side effects. All of the company's therapeutic candidates are based on this platform, with research and development activities concentrated on neuropsychiatric medicines. Seaport Therapeutics serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors.

Seaport Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol SPTX. The stock is traded in US Dollars (USD), reflecting its primary listing in the United States. As a company based in Boston, Massachusetts, and operating in the US healthcare sector, its financial reporting and trading currency are in USD.

Seaport Therapeutics operates in the Healthcare sector and specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing novel medicines for neuropsychiatric conditions. The biotechnology industry involves using biological processes and technologies to develop therapies, and Seaport's work with its Glyph platform to create treatments for depression and anxiety disorders places it firmly within this industry.

Seaport Therapeutics is headquartered in Boston, Massachusetts, United States. The company was founded in 2024 and operates primarily from this location. As a clinical-stage biopharmaceutical company, its research and development activities are centered in Boston, which is a major hub for biotechnology and life sciences innovation. The company serves clinicians and key opinion leaders in the healthcare and neuropsychiatric medicine sectors, primarily within the United States.